Capponi Vincent
Capponi Vincent, PRES, reported an open-market or private purchase at Cytosorbents Corp involving 273.000000 shares for an estimated $1610.70. Reported holdings after the transaction were 40387.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Sep 14, 2026
- Filing date
- Sep 16, 2026
How reported position traded is calculated
Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 40,114 shares.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
CTSO price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- Buy Code P
- Identifier
- 0001104659-26-108247 Common Stock
- Transaction date
- Sep 14, 2026 Filed Sep 16, 2026, 08:05 PM · 2d delay
- Shares
- 273 sh $5.90 per share
- Estimated value
- $1.61k Computed from shares × price
- Holdings after
- 40,387 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
+22 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
How this score is calculated
- open_market_purchase+12 points
transaction_code = P
Code P is a discretionary open-market purchase. - direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 2
Filing reported within two business days of the transaction.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
President and COO
- F1
This transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person.
- F2
Includes: (i) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Issuer") as defined in the Amended and Restated CytoSo…
- F3
(continued from footnote 2) (ii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the R…
- F4
(continued from footnote 3) (iii) 25,736 shares of Common Stock owned by the Reporting Person.
- F5
Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026.
0 other transactions
0 recent txs